BRAINLIFE.ORG




Current Neuro-Oncology




Volume 26 Number 6
31 March 2024




Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 6, 31 March








Zhu J, Ye J, Dong L, Ma X, Tang N, Xu P, Jin W, Li R, Yang G, Lai X.
Non-invasive prediction of overall survival time for glioblastoma multiforme patients based on multimodal MRI radiomics.
Int J Imaging Syst Technol. 2023 Mar 10;33(4):1261-1274. doi: 10.1002/ima.22869. PMID: 38505467. Observational study. ˍ




*Edström S, Hellquist BN, Sandström M, Sadanandan SA, Björkblom B, Melin B, Sjöberg RL.
Antidepressants and survival in glioma-A registry-based retrospective cohort study.
Neurooncol Pract. 2023 Aug 30;11(2):125-131. doi: 10.1093/nop/npad057. PMID: 38496917. Observational study. ˍ
Related article:
Rooney AG.
Antidepressants and survival in glioma: Unraveling a complex puzzle.
Neurooncol Pract. 2024 Feb 2;11(2):111-112. doi: 10.1093/nop/npae010. PMID: 38496915. Editorial˰ ˍ




Gilis N, Lebrun L, Lolli V, David P, Rodesch M, Bex A, Fricx C, De Maertelaer V, Salmon I, De Witte O.
Radiological characterization of pediatric intramedullary astrocytomas: Do they differ from adults?
Brain Spine. 2023 Sep 7;4:102671. doi: 10.1016/j.bas.2023.102671. PMID: 38510632. Observational study. ˍ




Peters KB, Alford C, Heltemes A, Savelli A, Landi DB, Broadwater G, Desjardins A, Johnson MO, Low JT, Khasraw M, Ashley DM, Friedman HS, Patel MP.
Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.
Neurooncol Pract. 2023 Oct 14;11(2):199-204. doi: 10.1093/nop/npad068. PMID: 38496920. Observational study˰ ˍ




Stadler C, Gramatzki D, Le Rhun E, Hottinger AF, Hundsberger T, Roelcke U, Läubli H, Hofer S, Seystahl K, Wirsching HG, Weller M, Roth P.
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
Neurooncol Pract. 2023 Oct 20;11(2):132-141. doi: 10.1093/nop/npad070. PMID: 38496908. Observational study. ˍ
Related article:
Roberto K, Perry JR.
A longer and/or better life for the oldest old with glioblastoma.
Neurooncol Pract. 2024 Jan 29;11(2):113-114. doi: 10.1093/nop/npae007. PMID: 38496918. Editorial˰ ˍ




*Omene E, Abdel-Rahman O, Batuyong E, Patel S, Coppens R, Easaw J, Young K.
Switch to generic formulation of temozolomide results in statistically significant increase in grade 3 and 4 bone marrow toxicity in glioma patients in the province of Alberta.
Neurooncol Pract. 2023 Oct 27;11(2):171-177. doi: 10.1093/nop/npad065. PMID: 38496912. Observational study. ˍ




Nair SM, Sahu A, Prasad A, George AM, Goel A, Gupta T.
Unusual Extra-Axial and Extracranial Recurrence in an IDH Mutant Astrocytoma: A Case Report.
Indian J Radiol Imaging. 2023 Dec 4;34(2):351-355. doi: 10.1055/s-0043-1777012. PMID: 38549893. Case report. ˍ




Bianconi A, Koumantakis E, Gatto A, Zeppa P, Saaid A, Nico E, Bruno F, Pellerino A, Rizzo F, Junemann CV, Melcarne A, Garbossa D, Dalmasso P, Cofano F.
Effects of Levetiracetam and Lacosamide on survival and seizure control in IDH-wild type glioblastoma during temozolomide plus radiation adjuvant therapy.
Brain Spine. 2023 Dec 14;4:102732. doi: 10.1016/j.bas.2023.102732. PMID: 38510602. Observational study. ˍ




Breen WG, Geno CS, Waddle MR, Qian J, Harmsen WS, Burns TC, Sener UT, Ruff MW, Neth BJ, Uhm JH, Routman DM, Yan E, Kruse JJ, Laack NN, Brown PD, Mahajan A.
Proton versus photon craniospinal irradiation for adult medulloblastoma: A dosimetric, toxicity, and exploratory cost analysis.
Neurooncol Adv. 2024 Mar 8;6(1):vdae034. doi: 10.1093/noajnl/vdae034. PMID: 38550393. Observational study. ˍ




Thomas-Joulié A, Tran S, El Houari L, Seyve A, Bielle F, Birzu C, Lozano-Sanchez F, Mokhtari K, Giry M, Marie Y, Laigle-Donadey F, Dehais C, Houillier C, Psimaras D, Alentorn A, Laurenge A, Touat M, Sanson M, Hoang-Xuan K, Kas A, Rozenblum L, Habert MO, Nichelli L, Leclercq D, Galanaud D, Jacob J, Karachi C, Capelle L, Carpentier A, Mathon B, Belin L, Idbaih A.
Prognosis of glioblastoma patients improves significantly over time interrogating historical controls.
Eur J Cancer. 2024 Mar 11;202:114004. doi: 10.1016/j.ejca.2024.114004. PMID: 38493668. Observational study. ˍ




Liu Y, Hu H, Han Y, Li Z, Yang J, Zhang X, Chen L, Chen F, Li W, Huang G.
Development and external validation of a novel score for predicting postoperative 30‑day mortality in tumor craniotomy patients: A cross-sectional diagnostic study.
Oncol Lett. 2024 Mar 12;27(5):205. doi: 10.3892/ol.2024.14338. PMID: 38516688. Observational study. ˍ




Edelbach B, Gospodarev V, Lopez-Gonzalez M, Deisch J, Kaur M.
Unusual presentation of glioblastoma in the brainstem: a case report of a diffuse pontine glioblastoma multiforme and surgical management.
Front Oncol. 2024 Mar 13;14:1279897. doi: 10.3389/fonc.2024.1279897. PMID: 38544840. Case report. ˍ




Ebaid NY, Ahmed RN, Assy MM, Amin MI, Eldin AMA, Alsowey AM, Abdelhay RM.
Diagnostic Validity and Reliability of BT-RADS in the Management of Recurrent High-Grade Glioma.
J Neuroradiol. 2024 Mar 14:S0150-9861(24)00111-1. doi: 10.1016/j.neurad.2024.03.001. PMID: 38492800. Observational study˰ ˍ




Mude P, Pradhan M, Tiwari A, Parida TK, Nayak MK, Sekar AK, Purkait S, Devi U.
Congenital brain tumour in a neonate: a therapeutic challenge.
BMJ Case Rep. 2024 Mar 15;17(3):e259646. doi: 10.1136/bcr-2024-259646. PMID: 38490704. Case report. ˍ




Caccese M, Desideri I, Villani V, Simonelli M, Buglione M, Chiesa S, Franceschi E, Gaviani P, Stasi I, Caserta C, Brugnara S, Lolli I, Bennicelli E, Bini P, Cuccu AS, Scoccianti S, Padovan M, Gori S, Bonetti A, Giordano P, Pellerino A, Gregucci F, Riva N, Cinieri S, Internò V, Santoni M, Pernice G, Dealis C, Stievano L, Paiar F, Magni G, De Salvo GL, Zagonel V, Lombardi G.
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
ESMO Open. 2024 Mar 15;9(4):102943. doi: 10.1016/j.esmoop.2024.102943. PMID: 38492275. Observational study. ˍ








Jang B, Yoon D, Lee JY, Kim J, Hong J, Koo H, Sa JK.
Integrative multi-omics characterization reveals sex differences in glioblastoma.
Biol Sex Differ. 2024 Mar 16;15(1):23. doi: 10.1186/s13293-024-00601-7. PMID: 38491408. Observational study. ˍ




*Zhu P, Pichardo-Rojas PS, Dono A, Tandon N, Hadjipanayis CG, Berger MS, Esquenazi Y.
The detrimental effect of biopsy preceding resection in surgically accessible glioblastoma: results from the national cancer database.
J Neurooncol. 2024 Mar 16. doi: 10.1007/s11060-024-04644-z. PMID: 38492191. Observational study˰ ˍ




*Cao W, Lan J, Hu C, Kong J, Xiang L, Zhang Z, Sun Y, Zeng Z, Lei S.
Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
Aging (Albany NY). 2024 Mar 18;16. doi: 10.18632/aging.205668. PMID: 38499392. Observational study. ˍ




Nemati M, Shayanfar M, Almasi F, Mohammad-Shirazi M, Sharifi G, Aminianfar A, Esmaillzadeh A.
Dietary patterns in relation to glioma: a case-control study.
Cancer Metab. 2024 Mar 18;12(1):8. doi: 10.1186/s40170-024-00336-4. PMID: 38500219. Observational study. ˍ




Van Genechten T, De Laere M, Van den Bossche J, Stein B, De Rycke K, Deschepper C, Hazes K, Peeters R, Couttenye MM, Van De Walle K, Roelant E, Maes S, Vanden Bossche S, Dekeyzer S, Huizing M, Caluwaert K, Nijs G, Cools N, Verlooy J, Norga K, Verhulst S, Anguille S, Berneman Z, Lion E.
Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
BMJ Open. 2024 Mar 18;14(3):e077613. doi: 10.1136/bmjopen-2023-077613. PMID: 38503417. Interventional study protocol. ˍ




*Bobholz SA, Lowman AK, Connelly JM, Duenweg SR, Winiarz A, Nath B, Kyereme F, Brehler M, Bukowy J, Coss D, Lupo JM, Phillips JJ, Ellingson BM, Krucoff MO, Mueller WM, Banerjee A, LaViolette PS.
Noninvasive Autopsy-Validated Tumor Probability Maps Identify Glioma Invasion Beyond Contrast Enhancement.
Neurosurgery. 2024 Mar 19. doi: 10.1227/neu.0000000000002898. PMID: 38501824. Observational study. ˍ




Geens W, Vanlaer N, Nijland L, Van Laere S, Schwarze JK, Bruneau M, Neyns B, Rogiers A, Duerinck J.
Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
J Neurooncol. 2024 Mar 19. doi: 10.1007/s11060-024-04646-x. PMID: 38502281. Observational study˰ ˍ




Roth P, Gorlia T, Reijneveld JC, de Vos F, Idbaih A, Frenel JS, Le Rhun E, Sepulveda JM, Perry J, Masucci GL, Freres P, Hirte H, Seidel C, Walenkamp A, Lukacova S, Meijnders P, Blais A, Ducray F, Verschaeve V, Nicholas G, Balana C, Bota DA, Preusser M, Nuyens S, Dhermain F, van den Bent M, O'Callaghan CJ, Vanlancker M, Mason W, Weller M; EORTC Brain Tumor Group and the Canadian Cancer Trials Group.
Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial.
Neuro Oncol. 2024 Mar 19:noae053. doi: 10.1093/neuonc/noae053. PMID: 38502052. Interventional study. ˍ




*Fairclough S, Chumas P, Goodden J, Maguire M, Mathew RK.
Motor seizures confer overall survival benefit in who grade 2 glioma.
Epilepsia. 2024 Mar 20. doi: 10.1111/epi.17956. PMID: 38506645. Observational study. ˍ




*Fink L, van Oorschot B, von Saß C, Dibué M, Foster MT, Golla H, Goldbrunner R, Senft C, Lawson McLean A, Hellmich M, Dinc N, Voltz R, Melching H, Jungk C, Kamp MA.
Palliative care for in-patient malignant glioma patients in Germany.
J Neurooncol. 2024 Mar 20. doi: 10.1007/s11060-024-04611-8. PMID: 38506960. Observational study. ˍ




Li MP, Yeo A, Gunewardena R, Drum G, Wiltshire K, Phillips C, Sia J, Wheeler G, Hall L.
Is proton beam therapy always better than photon irradiation? Lessons from two cases.
J Med Radiat Sci. 2024 Mar 20. doi: 10.1002/jmrs.773. PMID: 38504608. Case report. ˍ




Rejimon AC, Ramesh KK, Trivedi AG, Huang V, Schreibmann E, Weinberg BD, Kleinberg LR, Shu HG, Shim H, Olson JJ.
The Utility of Spectroscopic MRI in Stereotactic Biopsy and Radiotherapy Guidance in Newly Diagnosed Glioblastoma.
Tomography. 2024 Mar 20;10(3):428-443. doi: 10.3390/tomography10030033. PMID: 38535775. Observational study. ˍ




*Ryba A, Özdemir Z, Nissimov N, Hönikl L, Neidert N, Jakobs M, Kalasauskas D, Krigers A, Thomé C, Freyschlag CF, Ringel F, Unterberg A, Dao Trong P, Beck J, Heiland DH, Meyer B, Vajkoczy P, Onken J, Stummer W, Suero Molina E, Gempt J, Westphal M, Schüller U, Mohme M.
Insights from a Multicenter Study on Adult H3 K27M-Mutated Glioma: Surgical Resection's Limited Influence on Overall Survival, ATRX as Molecular Prognosticator.
Neuro Oncol. 2024 Mar 20:noae061. doi: 10.1093/neuonc/noae061. PMID: 38507506. Observational study˰ ˍ




Gull HH, Von Riegen AC, Beckmann GT, Ketelauri P, Walbrodt S, Santos AN, Oster C, Schmidt T, Glas M, Jabbarli R, Özkan N, Dammann P, Scheffler B, Sure U, Ahmadipour Y.
Treatment Strategies for Glioblastoma in the Elderly: What Should We Focus on Compared to Younger Patients.
Cancers (Basel). 2024 Mar 21;16(6):1231. doi: 10.3390/cancers16061231. PMID: 38539563. Observational study. ˍ




Kim D, Lee JH, Kim N, Lim DH, Song JH, Suh CO, Wee CW, Kim IA.
Optimizing Recurrent Glioblastoma Salvage Treatment: A Multicenter Study Integrating Genetic Biomarkers From the Korean Radiation Oncology Group (21-02).
Neurosurgery. 2024 Mar 21. doi: 10.1227/neu.0000000000002903. PMID: 38511935. Observational study˰ ˍ




Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, Cohen-Jonathan Moyal E, Bronnimann C, Di Stefano AL, Laurent I, Lerond J, Carpentier C, Bielle F, Ducray F, Dehais C; POLA Network.
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Eur J Cancer. 2024 Mar 22;202:114034. doi: 10.1016/j.ejca.2024.114034. PMID: 38537315. Interventional study˰ ˍ




*Straube C, Combs SE, Bernhardt D, Gempt J, Meyer B, Zimmer C, Schmidt-Graf F, Vajkoczy P, Grün A, Ehret F, Zips D, Kaul D.
Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.
J Neurooncol. 2024 Mar 23. doi: 10.1007/s11060-024-04633-2. PMID: 38520571. Observational study. ˍ




Desai PB, Karve A, Zawit M, Arora P, Dave N, Awosika J, Li N, Fuhrman B, Medvedovic M, Sallans L, Kendler A, DasGupta B, Plas D, Curry R, Zuccarello M, Chaudhary R, Sengupta S, Wise-Draper TM.
A Phase 0/1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-rade Gliomas.
Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3341. PMID: 38530160. Interventional study˰ ˍ




Wellbrock M, Voigt M, Ronckers C, Grabow D, Spix C, Erdmann F.
Registration, incidence patterns, and survival trends of central nervous system tumors among children in Germany 1980-2019: An analysis of 40 years based on data from the German Childhood Cancer Registry.
Pediatr Blood Cancer. 2024 Mar 26:e30954. doi: 10.1002/pbc.30954. PMID: 38532243. Observational study. ˍ




Alcazar-Felix RJ, Srinath A, Hage S, Bindal A, Ressler A, Pytel P, Allaw S, Girard R, Marchuk DA, Awad IA, Polster SP.
Pathologic Features of Brain Hemorrhage After Radiation Treatment: Case Series with Somatic Mutation Analysis.
J Stroke Cerebrovasc Dis. 2024 Mar 27:107699. doi: 10.1016/j.jstrokecerebrovasdis.2024.107699. PMID: 38552890. Observational study˰ ˍ




Troschel FM, Troschel BO, Kloss M, Jost J, Pepper NB, Völk-Troschel AS, Wiewrodt RG, Stummer W, Wiewrodt D, Eich HT.
Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients.
Strahlenther Onkol. 2024 Mar 28. doi: 10.1007/s00066-024-02225-7. PMID: 38546749. Observational study. ˍ




Evans L, Walker R, MacDiarmid J, Brahmbhatt H, Anazodo A, McCowage G, Gifford AJ, Kavallaris M, Trahair T, Ziegler DS.
A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor.
Target Oncol. 2024 Mar 28. doi: 10.1007/s11523-024-01051-2. PMID: 38546944. Interventional study. ˍ




Tong E, Horsley P, Wheeler H, Wong M, Venkatesha V, Chan J, Kastelan M, Back M.
Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
J Neurooncol. 2024 Mar 29. doi: 10.1007/s11060-024-04643-0. PMID: 38551747. Observational study˰ ˍ